Cabozantinib inhibits several tyrosine kinases that are biologically relevant in RCC, including VEGFRs, MET, and AXL,23 and is approved for use in advanced RCC, having demonstrated improved progression-free survival (PFS) versus standard-of-care sunitinib as a first-line treatment in patients with intermediate- or poor-risk metastatic CCRCC,24 and showing significant improvements in PFS, objective response rate (ORR), and overall survival (OS) when compared with everolimus in patients treated with prior anti-angiogenic therapy.25 This evidence concerns the gene MET and renal cell carcinoma.